The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma

Traeger, Max Michael; Rehkaemper, Jan; Ullerich, Hansjoerg; Steinestel, Konrad; Wardelmann, Eva; Senninger, N.; Dhayat, Sameer

doi:10.1007/s00432-018-2755-9

Cited by 11 publications

(7 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the same group reported that combination treatment of GEM and miR-205 [ 55 ], and EGFR-targeted co-delivery of miR-205 and GEM [ 174 ] effectively reduced the tumor growth in orthotopic mouse models. In contrast to the tumor suppressive role of miR-205 in pancreatic cancer, there are some studies that suggest that it has oncogenic and ambiguous roles in pancreatic cancer [ 175 , 176 , 177 ]. Additionally, few more studies confirmed miR-205 as a biomarker for pancreatic cancer [ 178 , 179 ].…”

Section: Tumor Suppressive Role Of Mir-205 In Different Cancersmentioning

confidence: 99%

miR-205: A Potential Biomedicine for Cancer Therapy

Chauhan

Dhasmana

Jaggi

et al. 2020

Cells

View full text Add to dashboard Cite

microRNAs (miRNAs) are a class of small non-coding RNAs that regulate the expression of their target mRNAs post transcriptionally. miRNAs are known to regulate not just a gene but the whole gene network (signaling pathways). Accumulating evidence(s) suggests that miRNAs can work either as oncogenes or tumor suppressors, but some miRNAs have a dual nature since they can act as both. miRNA 205 (miR-205) is one such highly conserved miRNA that can act as both, oncomiRNA and tumor suppressor. However, most reports confirm its emerging role as a tumor suppressor in many cancers. This review focuses on the downregulated expression of miR-205 and discusses its dysregulation in breast, prostate, skin, liver, gliomas, pancreatic, colorectal and renal cancers. This review also confers its role in tumor initiation, progression, cell proliferation, epithelial to mesenchymal transition, and tumor metastasis. Restoration of miR-205 makes cells more sensitive to drug treatments and mitigates drug resistance. Additionally, the importance of miR-205 in chemosensitization and its utilization as potential biomedicine and nanotherapy is described. Together, this review research article sheds a light on its application as a diagnostic and therapeutic marker, and as a biomedicine in cancer.

show abstract

Section: Tumor Suppressive Role Of Mir-205 In Different Cancersmentioning

confidence: 99%

miR-205: A Potential Biomedicine for Cancer Therapy

Chauhan

Dhasmana

Jaggi

et al. 2020

Cells

View full text Add to dashboard Cite

show abstract

“…MiRs are well-preserved, small non-coding RNAs that are about 22 nucleotides long and play a critical regulatory role in post-transcriptional inhibition of gene expression [10]. They have been attributed tumor-suppressive as well as oncogenic functions in multiple tumor entities and we have previously reported on their diagnostic and prognostic potential, as well as their influence on chemoresistance and epithelial-to-mesenchymal transition (EMT) in PDAC [11][12][13][14][15][16]. It is not without reason that miRs are of particular interest to researchers-circulating plasma or serum miRs can be stored at −80 • C for many years and are resistant to several freeze-thaw cycles and incubation at room temperature for over 24 h [17,18].…”

Section: Introductionmentioning

confidence: 99%

Potential of Exosomal microRNA-200b as Liquid Biopsy Marker in Pancreatic Ductal Adenocarcinoma

Reese

Flammang

Yang

et al. 2020

Cancers

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant tumor entity, characterized by rapid disease progression, early metastatic dissemination, and late diagnosis at advanced tumor stages. Recently, we explored the clinical impact of several microRNAs (miR) associated with proliferation, epithelial-to-mesenchymal transition (EMT), and chemoresistance in tissue and blood serum specimens of PDAC patients. Here, we evaluated the potential of these miRs as diagnostic and prognostic biomarkers in PDAC in serum exosomes and their respective EpCAM-positive (epithelial cell adhesion molecule) subset. Expression analysis by RT-qRT-PCR (real-time quantitative reverse transcription polymerase chain reaction) revealed an overexpression of miR-200b and miR-200c in serum exosomes of PDAC patients as compared to healthy controls (p < 0.001; p = 0.024) and patients with chronic pancreatitis (p = 0.005; p = 0.19). Receiver operating characteristic (ROC) curve analysis showed that a biomarker panel consisting of miR-200b and miR-200c from total and EpCAM-positive serum exosomes enhanced the diagnostic accuracy of carbohydrate antigen 19-9 (CA.19-9) to 97% (p < 0.0001). Univariate survival analysis revealed a correlation between shorter overall survival (OS) and high expression of miR-200c in total serum exosomes (p = 0.038) and miR-200b in EpCAM-positive serum exosomes (p = 0.032), whereas EpCAM exosomal miR-200b was also indicative of shorter OS in the subgroup of patients treated with curative intent (p = 0.013). Multivariate survival analysis showed that miR-200b derived from EpCAM-positive serum exosomes might serve as an independent prognostic factor in PDAC (p = 0.044). Our findings indicate a potential role of exosomal miR-200 as diagnostic and prognostic liquid biopsy marker in PDAC and call for validation in a larger, multicenter setting.

show abstract

“…Recently, another panel (FGA, KRT19, HIST1H2BK, ITIH2, MARCH2, CLDN1, MAL2 and TIMP1) obtained by plasma extracellular vesicle long RNA profiling (d-signature), successfully differentiated PDAC from CP and healthy controls with AUC of 0.936, and both SN and SP > 90%; furthermore, when combined with CA19-9, the signature showed improved AUC of 0.964 (95% CI: 0.943–0.984) [ 80 ]. Traeger et al, reported that miRNA-205 combined with CA19-9 resulted in higher SN and SP in comparison of PDAC vs. benign specimens (86.7% SN and 93.3% SP) than either of the biomarkers alone [ 75 ].…”

Section: Resultsmentioning

confidence: 99%

“… ☺ ☺ ☺ High 39 Mellby et al, 2018 [ 74 ] ☺ ? ☺ ☺ ☺ ☺ Low 40 Traeger et al, 2018 [ 75 ] ☺ ☹ ☺ ☺ ☺ ☺ Low 41 Zhou et al, 2018 [ 76 ] ☺ ☹ ☺ ☹ ? ☺ High 42 Berger et al, 2019 [ 77 ] …”

Section: Table A1mentioning

confidence: 99%

Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer—A Comprehensive Review

Brezgyte

Shah

Jach

et al. 2021

Cancers

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) carries a deadly diagnosis, due in large part to delayed presentation when the disease is already at an advanced stage. CA19-9 is currently the most commonly utilized biomarker for PDAC; however, it lacks the necessary accuracy to detect precursor lesions or stage I PDAC. Novel biomarkers that could detect this malignancy with improved sensitivity (SN) and specificity (SP) would likely result in more curative resections and more effective therapeutic interventions, changing thus the present dismal survival figures. The aim of this study was to systematically and comprehensively review the scientific literature on non-invasive biomarkers in biofluids such as blood, urine and saliva that were attempting earlier PDAC detection. The search performed covered a period of 10 years (January 2010—August 2020). Data were extracted using keywords search in the three databases: MEDLINE, Web of Science and Embase. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was applied for study selection based on establishing the risk of bias and applicability concerns in Patient Selection, Index test (biomarker assay) and Reference Standard (standard-of-care diagnostic test). Out of initially over 4000 published reports, 49 relevant studies were selected and reviewed in more detail. In addition, we discuss the present challenges and complexities in the path of translating the discovered biomarkers into the clinical setting. Our systematic review highlighted several promising biomarkers that could, either alone or in combination with CA19-9, potentially improve earlier detection of PDAC. Overall, reviewed biomarker studies should aim to improve methodological and reporting quality, and novel candidate biomarkers should be investigated further in order to demonstrate their clinical usefulness. However, challenges and complexities in the path of translating the discovered biomarkers from the research laboratory to the clinical setting remain and would have to be addressed before a more realistic breakthrough in earlier detection of PDAC is achieved.

show abstract

The ambiguous role of microRNA-205 and its clinical potential in pancreatic ductal adenocarcinoma

Cited by 11 publications

References 54 publications

miR-205: A Potential Biomedicine for Cancer Therapy

miR-205: A Potential Biomedicine for Cancer Therapy

Potential of Exosomal microRNA-200b as Liquid Biopsy Marker in Pancreatic Ductal Adenocarcinoma

Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer—A Comprehensive Review

Contact Info

Product

Resources

About